Over the years, Nventa’s has devoted substantial management attention and resources to maintaining patents and licenses and conducting an assertive patent prosecution strategy. As a result, Nventa has a strong and growing global patent portfolio protecting its proprietary technology, including its HspE7 candidate and applications of its CoVal™ fusions for the treatment of hepatitis B and influenza.

Selected Patents:

Stress Proteins and Uses Therefor
6,335,183

Stress Proteins and Uses Therefor
6,338,952

Stress Proteins and Uses Therefor
6,482,614

Induction of a Th1-Like Response
6,495,347

Immune Responses Against HPV Antigens Elicited by Compositions Comprising an HPV Antigen and a Stress Protein or an Expression Vector Capable of Expression of These Proteins
6,524,825

Induction of a Th1-Like Response
6,657,055

Human Papilloma Virus Treatment
6,797,491

Immune Responses Against HPV Antigens Elicited by Compositions Comprising an HPV Antigen and a Stress Protein or an Expression Vector Capable of Expression of These Proteins
6,900,035

Hepatitis B Virus Treatment
6,921,534

Immune Responses Using Compositions Comprising Stress Proteins
7,157,089

Human Papilloma Virus Treatment
7,211,411

Immune Responses Against HPV Antigens Elicited by Compositions Comprising an HPV Antigen and a Stress Protein or an Expression Vector Capable of Expression of These Proteins
7,262,014